Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
Navican is hoping to bring some of the genomic testing and related services Intermountain has been offering for three years to the broader cancer community.
A Counsyl study suggests that just half of individuals go through with insurance-mandated pretest genetic counseling, paying out of pocket or canceling the test instead.
This year, the vast majority of assays the Belgian company facilitates will be non-invasive prenatal testing, which it only started offering in 2013.
Under the Color Family Testing Program, family members of patients who tested positive for a gene on Color's hereditary cancer test can be tested for $50.
Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.
In a complaint filed yesterday, Foundation claims that the Guardant360 test infringes its US Patent No. 9,340,830.
The company reported 8,985 clinical tests in the first quarter, a 14 percent year-over-year increase.
Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.
A year after launching the test in the US, the company is making it available in more than 100 countries, partnering with distributors in Israel, Turkey, and Finland.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.